TY - JOUR
T1 - Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
AU - Kochanowska, Anna
AU - Rusztyn, Przemysław
AU - Szczerkowska, Karolina
AU - Surma, Stanisław
AU - Gąsecka, Aleksandra
AU - Jaguszewski, Miłosz J.
AU - Szarpak, Łukasz
AU - Filipiak, Krzysztof J.
N1 - Publisher Copyright: © 2023 by the authors.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are glucose-lowering agents whose positive impact on cardiovascular risk has been described extensively. Not only do they influence lipid profile, blood pressure, atherosclerosis risk, hemoglobin level, and insulin resistance, but they also reduce cardiovascular events, all-cause mortality, and hospitalization rates. Some of these effects may be due to their impact on serum uric acid (SUA) concentration. Findings from nine meta-analyses showed that, indeed, SGLT2is significantly reduce SUA. The data on the drug- and dose-dependency of this effect were inconclusive. Several factors alternating the beneficial effects of SGLT2is on SUA, such as glycated hemoglobin concentration (HbA1c), presence of diabetes, and baseline SUA level, were described. Even though there is a consensus that the lowering of SUA by SGLT2is might be due to the increased urinary excretion rate of uric acid (UEUA) rather than its altered metabolism, the exact mechanism remains unknown. The influence of SGLT2is on SUA may not only be used in gout treatment but may also be of huge importance in explaining the observed pleiotropic effects of SGLT2is.
AB - Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are glucose-lowering agents whose positive impact on cardiovascular risk has been described extensively. Not only do they influence lipid profile, blood pressure, atherosclerosis risk, hemoglobin level, and insulin resistance, but they also reduce cardiovascular events, all-cause mortality, and hospitalization rates. Some of these effects may be due to their impact on serum uric acid (SUA) concentration. Findings from nine meta-analyses showed that, indeed, SGLT2is significantly reduce SUA. The data on the drug- and dose-dependency of this effect were inconclusive. Several factors alternating the beneficial effects of SGLT2is on SUA, such as glycated hemoglobin concentration (HbA1c), presence of diabetes, and baseline SUA level, were described. Even though there is a consensus that the lowering of SUA by SGLT2is might be due to the increased urinary excretion rate of uric acid (UEUA) rather than its altered metabolism, the exact mechanism remains unknown. The influence of SGLT2is on SUA may not only be used in gout treatment but may also be of huge importance in explaining the observed pleiotropic effects of SGLT2is.
KW - SGLT2i
KW - flozins
KW - gout
KW - sodium–glucose cotransporter 2 inhibitors
KW - uric acid
UR - http://www.scopus.com/inward/record.url?scp=85166400734&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/jcdd10070268
DO - https://doi.org/10.3390/jcdd10070268
M3 - Review article
C2 - 37504524
SN - 2308-3425
VL - 10
JO - Journal of cardiovascular development and disease
JF - Journal of cardiovascular development and disease
IS - 7
M1 - 268
ER -